このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

CD34選択による動員末梢血幹細胞のEx Vivo T細胞枯渇 (EXCESS)

2026年11月11日 更新者:Robert Krance、Baylor College of Medicine

CD34 選択 (EXCESS) による動員末梢血幹細胞の Ex Vivo T 細胞枯渇

Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant. Stem cells or "mother" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation. Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) for the participant and his or her disease does not permit enough time to identify another donor (like someone from a registry list that is not his or her relative) or another suitable donor has not been identified. However, a close relative of the patient has been identified whose stem cells are not a perfect match, but can be used.

Alternatively, the patient may have already received a stem cell transplant but have evidence of mixed chimerism, which means some of the patient's own bone marrow cells are present, rather than all of the donor's cells. This may lead to an increased risk of the disease coming back. Or, the patient may have all donor cells but his or her bone marrow is not working very well, which may lead to frequent blood or platelet (cells that help in clotting blood) transfusions or infection.

Regardless of the reason, it may be necessary to isolate stem cells from a haploidentical (half-match) donor in order to provide bone marrow function. Because the stem cells from the donor are only half-matched to the participant, the risk of graft-versus-host disease (GvHD) is very high. GvHD is a complication after transplant caused by donor T cells (graft) that attack the transplant recipient, and this complication can cause death after transplant. Thus, it is important that the donor's blood cells are treated to minimize cells that are most likely to attack the host's tissues. This is done by using a special device to capture the CD34+ stem cells from the donor's stem cell product prior to giving the cells to the host. This method minimizes the donor T cells, which are responsible for causing GvHD.

Purpose: In an effort to lower the occurrences and severity of graft-versus-host disease in patients and to lower the rate of transplant failure, investigators would like to specially treat the donor's blood cells to minimize the cells that are most likely to attack the patient's tissues.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Participation in this project will last approximately one year with follow-up exams.

Before treatment can begin, stem cells will be collected from the donor (a close relative) that has been selected as the best match for the participant. White blood cells will be collected from the donor. The cells will then be mixed with a special protein, called a CD34 antibody, that binds to the stem cells, which will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory. This is an investigational device that is not approved by the FDA. Although this device is not approved for use in this country, it has been in use for years and is approved in other countries. The stem cells will be collected and given fresh or they can be frozen before they will be given to the participant.

On about days 28, 60, 100, 180 and 365 after the transplant, the participant will have the same tests/evaluations since the time of transplant. For patients who do not develop GvHD, they are not required to have these tests/evaluations.

In addition, for purposes of the study, health-related information will be collected for a year from the time of stem cell infusion. This will be used to determine survival, relapse, infections and GvHD that may occur following transplant.

研究の種類

介入

入学 (推定)

241

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Marlen Dinu
  • 電話番号:832-824-4881
  • メール:mxdinu@txch.org

研究連絡先のバックアップ

  • 名前:Robert Krance, MD
  • 電話番号:832-824-4661
  • メール:rakrance@txch.org

研究場所

    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • Houston Methodist Hospital
        • コンタクト:
        • コンタクト:
      • Houston、Texas、アメリカ、77030
        • 募集
        • Texas Children's Hospital
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

70年歳未満 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)

  1. Patient requiring allogeneic SCT
  2. Age between birth and 70 years
  3. Patient and/or responsible person able to understand and sign consent

Exclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)

  1. Active, acute GvHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Pulmonary dysfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)
  4. Cardiac dysfunction (LVSF less than 25%)
  5. Psychiatric disturbance
  6. Lansky or Karnofsky score < 50%
  7. The presence of severe hepatic disease (direct bilirubin >3x upper limit of normal and AST > 5x upper limit of normal).
  8. Creatinine > 3x normal
  9. Known HIV Positivity
  10. Pregnancy

Inclusion Criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)

  1. Allogeneic SCT Recipient requiring additional cellular therapy

  2. Age between birth and 70 years

  3. Patient and/or responsible person able to understand and sign consent

  4. At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:

    1. Evidence of mixed chimerisms (less than 95% donor cells)
    2. Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)
    3. Relapsed or persistent disease

Exclusion criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)

  1. Active, acute GvHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Known HIV positivity
  4. Pregnancy

Inclusion Criteria for CD34+ Topoff WITH conditioning (COHORT 3)

  1. Allogeneic SCT Recipient requiring additional cellular therapy

  2. Age between birth and 70 years

  3. Patient and/or responsible person able to understand and sign consent

  4. At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:

    1. Evidence of mixed chimerisms (less than 95% donor cells)
    2. Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)
    3. Relapsed or persistent disease

Exclusion criteria for CD34+ Topoff WITH Conditioning (COHORT 3)

  1. Active, acute GVHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Pulmonary disfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)
  4. Cardiac dysfunction (LVSF less than 25%)
  5. Psychiatric disturbance
  6. Lansky or Karnofsky score < 50%
  7. The presence of severe hepatic disease (direct bilirubin > 3x upper limit of normal and AST > 5x upper limit of normal)
  8. Creatinine > 3x normal
  9. Known HIV positivity
  10. Pregnancy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 2: CD34+ cells as a top off Without Conditioning

Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a "topoff" without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.

A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

実験的:Cohort 1: CD34+ Cells for transplant

Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.

A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

実験的:Cohort 3: CD34+ cells as a top off With Conditioning

Cohort 3 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD 34+ Reagent System' as a "topoff" with the need for additional conditioning prior to the infusion. These patients who have already received SCT with conditioning and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.

A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
For Cohort 1: the rate of primary engraftment 50 days post SCT
時間枠:50 days

Primary engraftment is defined as achievement of absolute neutrophil count (ANC) is greater than or equal to 500/ul for three consecutive days by day 50 post transplant. The treatment regimen will be considered clinically useful if the primary engraftment rate is at least 85%.

50 days
For Cohort 2 (Without Conditioning) and Cohort 3 (With Conditioning): The total incidence of overall acute GvHD (greater than or equal to grade 3)
時間枠:100 days

The overall incidence of acute GvHD will be measured 100 days post stem cell transplant. The regimen will be considered acceptable if aGvHD greater than or equal to grade 3 rate is at least 10% or lower.

100 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Assessment of Long Term Survival
時間枠:1 year

Long term survival of recipients of G-CSF mobilized peripheral blood stem cells depleted of T cells by positive selection for the CD34+ antigen

1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Robert Krance, MD、Baylor College of Medicine

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2010年10月1日

一次修了 (推定)

2027年10月1日

研究の完了 (推定)

2027年11月1日

試験登録日

最初に提出

2010年8月25日

QC基準を満たした最初の提出物

2010年8月25日

最初の投稿 (推定)

2010年8月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • H-27251 EXCESS
  • EXCESS (その他の識別子:Baylor College of Medicine)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。